Monthly Investment Overview
A.L.F.R.E.D. equity market regime assessment for October 2026
Portfolio manager's note
Contributors and detractors
CSL Limited, +0.25% Betashares Global Energy Companies ETF, +0.20% Aristocrat Leisure, +0.19% Pro Medicus, +0.18% Global X Ultra Short Nasdaq hedge, +0.15%
Tuas Limited, -0.75% Solstice Minerals, -0.28% DPM Metals, -0.25% SKS Technologies, -0.23% DXN, -0.21%
Strategy vs benchmark, since inception
Total returns of the Avangard Australian equity strategy against the S&P/ASX 200 Accumulation Index.
| Period | Strategy | Benchmark | Alpha |
|---|---|---|---|
| 1 Month | -3.69% | +1.38% | -5.06% |
| 3 Months | -7.18% | +0.45% | -7.64% |
| 6 Months | -7.79% | +4.60% | -12.39% |
| 1 Year | -11.48% | +3.69% | -15.18% |
| FY 2025/26 | +15.91% | +6.11% | +9.80% |
| Since inception (cumulative) | +3.22% | +12.29% | -9.07% |
| Since inception (p.a.) | +1.81% | +6.77% | -4.97% |
Track record stitches the closed Avangard Alpha Fund (23 Jan 2025 to its final pricing date, 25 Jun 2026) with the current Avangard Systematic Australian Equity Fund from 6 Jul 2026. Cumulative is the total return since 23 Jan 2025; p.a. is the annualised equivalent of that same return. All periods are point to point to the report month end, so trailing periods that exclude the 2025 drawdown can exceed the since inception figure. Returns are calculated from unit prices and are net of all fees, including management and performance fees. Past performance is not indicative of future results.
Growth of A$1,000,000 since 23 January 2025
Month-end NAV unit price series. Strategy stitches the closed Avangard Alpha Fund with the Avangard Systematic Australian Equity Fund (NAV restarts at $1.0000 from Jul 2026), plotted against the S&P/ASX 200 Accumulation Index.
Hypothetical growth of A$1,000,000 invested at strategy inception (23 Jan 2025), using month-end NAV unit prices. Past performance is not a reliable indicator of future returns.
Exposure at month end
Top 5 holdings
Ranked by weight of gross asset value at month end.
| # | Code | Security | Weight |
|---|---|---|---|
| 1 | CSL | CSL Ltd | 3.1% |
| 2 | PME | PRO MEDICUS LTD | 3.0% |
| 3 | FUEL | Betashares Global Energy Comp Currency Hedged ETF | 3.0% |
| 4 | SNAS | Global X Ultra Short Nasdaq 100 Complex ETF | 3.0% |
| 5 | ANZ | ANZ GROUP HOLDINGS LTD | 2.9% |
Large / mid / small cap exposure
Direct Australian stock sleeve by S&P/ASX index tier. Excludes ETFs, LICs and cash.
Direct stocks = 25.5% of portfolio. Bars below show the composition of that sleeve.
- Large (ASX 50)83.7%
- Mid (ASX 51-100)16.3%
Portfolio breakdown
Sector uses GICS for direct stocks. All ETFs are aggregated as 'Thematic ETFs'.
Asset class
3 groupsSector / theme
9 groupsPerformance figures shown are for the Avangard Australian equity strategy and combine the closed Avangard Alpha Fund (23 January 2025 to its final pricing date, 25 June 2026) with the current Avangard Systematic Australian Equity Fund from 6 July 2026. The benchmark shown is the S&P/ASX 200 Accumulation Index. Alpha is calculated as strategy return minus benchmark return over the same period. Strategy returns are calculated from unit prices and are net of all fees, including management and performance fees.
Past performance is not a reliable indicator of future performance. Returns are historical, are not guaranteed and may vary. Portfolio holdings, sector and market-cap allocations shown are point-in-time at month end and will change without notice.
This report is issued by Avangard Investments Pty Ltd (ACN 698 681 248), a corporate authorised representative (CAR No. 001321538) of FB Corp Limited (ABN 16 675 876 490, AFSL 557810), and is available to wholesale clients only under s761G of the Corporations Act 2001 (Cth). It is general information and does not take account of the objectives, financial situation or needs of any particular person. You should consider the appropriateness of the information having regard to your own circumstances before making any investment decision.
